Novavax Inc. said on Tuesday its updated protein-based COVID-19 vaccine generated an immune response against emerging forms of coronavirus such as the “Eris” subvariant in small studies in animals.
Today’s announcement by the World Health Organization is a major step towards the end of the pandemic that has killed more than 6.9 million people, disrupted the global economy and ravaged communities.
Pfizer beat estimates for first-quarter profit, helped by steady demand for its COVID products and said it expects newer drugs to contribute to growth later this year, sending its shares up nearly 3% in premarket trading.
Wow, this headline is ironic. I wrote it March 27, 2023. I took the photo March 29, 2023. After successfully ducking the ’vid for three years, the ’vid found me.
The early-stage study, which is being sponsored by BioNTech, aims to evaluate the combination shot’s safety, tolerability and immunogenicity, or the ability to generate immune response.
The top pharma companies in 2021 continued to be engaged in creating vaccines and therapeutics, and the investments in R&D led to greater revenue and earnings.
Company CEO Albert Bourla has received four doses of the COVID vaccine developed by Pfizer and its German partner BioNTech but said he has not yet taken the new bivalent booster.
Updated data released on Tuesday showed 13 children had COVID-19, at least seven days after receiving a third dose of the Pfizer-BioNTech COVID-19 vaccine, compared with 21 cases among those who received a placebo.
Combined with 105 million doses the government already agreed to buy from Pfizer Inc. and partner BioNTech SE for $3.2 billion, the latest deal puts the U.S. booster dose supply at about 171 million shots.
The COVAX facility, backed by the World Health Organization and the Global Alliance for Vaccines and Immunization, has delivered 1.55 billion COVID-19 vaccine doses to 146 countries. In December, COVAX set a target of achieving 70% COVID-19 immunization coverage by mid-2022.